Table 1 Baseline characteristics.

Age (years), median, (Q1; Q3)

64 (60; 69)

59 (50; 71)

0.527

Sex, n (%)

Male

14 (70%)

11 (57.9%)

0.514

Female

6 (30%)

8 (42.1%)

BMI (kg/m²), median, (Q1; Q3)

24.8 (22.5; 28.1)

25.5 (22.3; 28.69)

0.989

Smoking, n (%)

5 (25%)

2 (10.5%)

0.407

CCI, n (%)

< 6

19 (95%)

15 (78.9%)

0.182

≥ 6

1 (5%)

4 (21.1%)

cT, n (%)

2

2 (10%)

2 (10.5%)

0.713

3

14 (70%)

15 (78.9%)

4

4 (20%)

2 (10.5%)

cN, n (%)

0

6 (30%)

4 (21.1%)

0.716

1–3

14 (70%)

15 (78.9%)

cM, n (%)

0

18 (90%)

19 (100%)

0.487

1

2 (10%)

0 (0%)

Clinical stage by TNM, n (%)

2

15 (75%)

12 (63.2%)

0.142

3

3 (15%)

7 (36.8%)

4

2 (10%)

0 (0%)

Tumor localization, n (%)

Upper third

5 (25%)

1 (5.3%)

0.195

Middle third

7 (35%)

7 (36.8%)

Lower third

8 (40%)

9 (47.4%)

Total

0 (0%)

2 (10.5%)

Poorly cohesive gastric carcinoma, n (%)

6 (30%)

6 (31.6%)

0.915

Signet ring cell carcinoma, n (%)

3 (15%)

3 (15.8%)

0.999

HER2 positive gastric cancer, n (%)

0 (0%)

0 (0%)

0.999

Baseline neutrophile level (x10⁹/l), median (Q1; Q3)

5.56 (4.91; 7.60)

4.16 (3.25; 5.49)

0.008

Baseline lymphocyte level (x10⁹/l), median (Q1; Q3)

1.32 (1.08; 1.87)

2.01 (1.10; 2.35)

0.351

Baseline hemoglobin (g/l) level, median (Q1; Q3)

127 (117; 143)

131 (117; 142)

0.569

Baseline platelet level (x10⁹/l), median (Q1; Q3)

238 (194; 299)

281 (212; 296)

0.667

Baseline C reactive protein level (mg/l), median (Q1; Q3)

1.0 (0.6; 3.3)

1.3 (0.6; 2.4)

0.989

Baseline serum albumin level (g/l), median (Q1; Q3)

42 (40; 44)

45 (44; 47)

0.003